Form 4: Director Katherine Eade Receives HBIO Equity Grant

Harvard Bioscience director Katherine A. Eade was granted 16,556 restricted stock units as part of standard equity compensation.

Summary

• Director Katherine A. Eade acquired 16,556 restricted stock units (RSUs) on June 9, 2026.
• The grant was issued at a price of $0.00 per share.
• Following this transaction, the director's total beneficial ownership increased to 58,669 shares.
• The filing confirms the impact of a 10-for-1 reverse stock split that occurred on March 13, 2026.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral, routine administrative filing regarding director compensation that does not signal a change in company strategy or financial health.

Positives

• Alignment of director interests with shareholders through equity-based compensation.
• Transparent disclosure of director holdings following a corporate action (reverse stock split).

Negatives

• None identified; this is a routine compensatory filing.

Risks

• None identified; this is a routine compensatory filing.

Future Outlook

The RSUs vest in full either immediately prior to the company's next annual meeting or one year from the date of grant, whichever is earlier.

Industry Context

StockSavvy.ai notes that equity grants to non-employee directors are standard corporate governance practices in the life sciences sector to ensure long-term alignment with shareholder value.

Comparison to Industry Standards

• The use of RSU grants for board compensation is consistent with standard practices for small-cap biotechnology and life science tool companies.
• The vesting schedule (one year or next annual meeting) is standard for director equity awards.

Stakeholder Impact

• Minimal impact on shareholders; represents standard director compensation.

Next Steps

• Vesting of the 16,556 RSUs at the next annual meeting or June 9, 2027.

Key Dates

Keywords

Harvard Bioscience, HBIO, Form 4, Director Compensation, Restricted Stock Units, Insider Ownership